KR960701653A - 펩타이드 yy의 유사체 및 그의 용도 - Google Patents
펩타이드 yy의 유사체 및 그의 용도Info
- Publication number
- KR960701653A KR960701653A KR1019950704035A KR19950704035A KR960701653A KR 960701653 A KR960701653 A KR 960701653A KR 1019950704035 A KR1019950704035 A KR 1019950704035A KR 19950704035 A KR19950704035 A KR 19950704035A KR 960701653 A KR960701653 A KR 960701653A
- Authority
- KR
- South Korea
- Prior art keywords
- arg
- leu
- compound
- lys
- homo
- Prior art date
Links
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 title 1
- 108010088847 Peptide YY Proteins 0.000 title 1
- 102100029909 Peptide YY Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 7
- 239000003792 electrolyte Substances 0.000 claims abstract 3
- 230000004663 cell proliferation Effects 0.000 claims abstract 2
- 230000004130 lipolysis Effects 0.000 claims abstract 2
- 235000015097 nutrients Nutrition 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 10
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 9
- 125000002252 acyl group Chemical group 0.000 claims 8
- 125000002877 alkyl aryl group Chemical group 0.000 claims 8
- -1 aromatic amino acid Chemical class 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000032258 transport Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
본 발명은 PYY의 유사체에 관계한다. 본 발명은 또한 세포증식, 영양분수송, 지방분해 및 장수 및 전해질 분배와 같은 생물학적 활성을 조절하는 유용한 조성물 및 방법을 제공한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (20)
- 하기 식의 화합물:상기 식에서, X는 R1및 R2에 결합되어 있는 N-말단 아미노산을 포함하는 0-5 아미노산 쇄이고; Y는 R3및 R4에 결합되어 있는 C-말단 아미노산을 포함하는 0-4 아미노산 쇄이며; R1은 H, C1-C12알킬, C6-C18아릴, C1-C12아실, C7-C18아랄킬, 또는 C7-C18알카릴이고; R2은 H, C1-C12알릴, C6-C18아릴, C1-C12아실, C7-C18아랄킬, 또는 C7-C18알카릴이며; A22는 방향족 아미노산, Ala, Aib, Anb, N-Me-Ala이거나 또는 결실되고; A23은 Ser, Thr, Ala, Aib, N-Me-Ser, N-Me-Thr, N-Me-Ala, 또는 결실되며; A24는 Leu, Gly, Ile, Val, Trp, Aib, Anb, N-Me-Leu, 또는 결실되고, A25는 Arg, Lys, home-Arg, diethyl-homo-Arg, Lys-ε-NH-R(여기서, R은 H, 가지난 또는 곧은 쇄 C1-C10알킬기, 또는 아릴기이다), Orn, 또는 결실되며; A26은 Ala, His, Thr, 3-Me-His, 1-Me-His, β-pyrozolylalnine, N-Me-His, Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-ε-NH-R(여기서, R은 H, 가지 난 또는 곧은 쇄 C1-C10알킬기, 또는 아릴기이다), Orn, 또는 결실되고; A27은 Tyr 이외의 방향족 아미노산이미; A28은 Leu, Ile, Val, Trp, Aib, Anb, 또는 N-Me-Leu이고; A29은 Asn, Ala, Gln, Gly, Trp, 또는 N-Me-Asn이며; A30은 Leu, Ile, Val, Trp, Aib, Anb, 또는 N-Me-Leu이고; A31은 Val, Ile, Trp, Aib, Anb 또는 N-Me-Val이며; A32는 Thr, Ser, N-Me-Ser, N-Me-Thr, 또는 D-Trp이고; R3은 또 C1-C12알킬, C6-C18아릴, C1-C12아실, C7-C18아랄킬, 또는 C7-C18알카릴이며; 및 R4은 H, C1-C12알킬, C6-C18아릴, C1-C12아실, C7-C18아랄킬, C7-C18알카릴 또는 그의 약제학상 허용되는 염이다.
- 제1항에 있어서. 상기 A27이 Phe, Nal, Bip, Pcp, Tic, Trp, Bth, Thi 또는 Dip인 화합물.
- 제1항에 있어서, X는 A17-A18-A19-A20-A21로서, 여기서, A17은 Cys, Leu, Ile, VaL Aib, Anb, 또는 N-Me-Leu이고; A18은 Cys, Ser, Thr, N-Me-Ser, 또는 N-Me-Thr이며; A19는 Cys, Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-ε-NH-R(여기서, R은 H, 가지난 또는 곧은 쇄 C1-C10알킬기, 또는 아릴기이다), 또는 Orn이고; A20은 방향족 아미노산 또는 Cys이며; 및 A21은 방향족 아미노산, Cys 또는 그의 약제학상 허용되는 염의 화합물.
- 제1항에 있어서, Y는 A33-A34-A35-A36으로서, 여기서, A33은 Cys, Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-ε-NHR(여기서, R은 H, 가지난 또는 곧은 쇄 C1-C10알킬기, 또는 아릴기이다), 또는 Orm이고; A34는 Cys, Gln, Asn, Ala, Gly, N-Me-Gln, Aib 또는 Anb이며; A38는 Cys, Arg, Lys, homo-Arg, diethyl-home-Arg, Lys-ε-NH-R(여기서, R은 H, 가지난 또는 곧은 쇄 C1-C10알킬기, 또는 아릴기이다), 또는 Orn이고; 및 A38은 방향족 아미노산, Cys 또는 그들의 약제학상 허용되는 염의 화합물.
- 제4항에 있어서, 상기 화합물이 하기 식을 갖는 화합물; N-α-Ac-Ala-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2(서열확인번호 3), 또는 그의 약제학상 허용되는 염.
- 제4항에 있어서, 상기 화합물이 하기 식을 갖는 화합물; H-Ala-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2(서열확인번호 4), 또는 그의 약제학상 허용되는 염.
- 제4항에 있어서, 상기 화합물이 하기 식을 갖는 화합물: N-α-Ac-Ala-Ser-Leu-Arg-His-Trp-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2(서열확인번호 5), 또는 그의 약제학상 허용되는 염.
- 제4항에 있어서, 상기 화합물이 하기 식을 갖는 화합물: N-α-Ac-Ala-Ser-ku-Arg-His-Trp-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2(서열확인번호 6), 또는 그의 약제학상 허용되는 염.
- 제4항에 있어서, 상기 화합물이 하기 식을 갖는 화합물; N-α-Ac-Tyr-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2(서열확인번호 7), 또는그의 약제학상 허용되는 염.
- 하기 식을 갖는 화합물:상기 식에서, N-말단 아미노산은 R1및 R2에 결합되어 있고; Y는 R3및 R4에 결합되어 있는 C-말단 아미노산을 포함하는 0-4 아미노산 쇄이며; R1은 H, C1-C12알킬, C6-C18아릴, C1-C12아실, C7-C18아랄킬, 또는 C7-C18, 알카릴이고; R2은 H, C1-C12알릴, C6-C18아릴, C1-C12아실, C7-C18아랄킬, 또는 C7-C18알카릴이며; A25는 Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-ε-NH-R(여기서, R은 H, 가지난 또는 곧은 쇄 C1-C10알킬기, 또는 아릴기이다), Orn이거나 또는 결실되고; A26은 Ala, His, Thr, 3-Me-His, 1-Me-His, β-pyrozolyhlalaine, N-Me-His, Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-ε-NH-R(여기서, R은 H, 가지난 또는 곧은 쇄 C1-C10알킬기, 또는 아릴기이다), Orn이거나, 또는 결실되고; A27은 방향족 아미노산이며; A28은 Leu, Ile, Val, Trp, Aib, Anb, 또는 N-Me-Leu이고; A29은 Asn, Ala, Gln, Gly, Trp, 또는 N-Me-Asn이며; A30은 Leu, Ile, Val, Trp, Aib, Anb, 또는 N-Me-Leu이고; A31은 Val, Ile, Trp, Aib, Anb 또는 N-Me-Val이며; A32는 Thr, Ser, N-Me-Ser, N-Me-Thr, 또는 D-Trp이고; R3은 H, C1-C12알킬, C6-C18아릴, C1-C12아실, C7-C18아랄킬, 또는 C7-C18알카릴이며; 및 R4은 H, C1-C12알킬, C6-C18아릴, C1-C12아실, C7-C18아랄킬, C7-C18알카릴 또는 그의 약제학상 허용되는 염이다.
- 제10항에 있어서, A27은 Phe, Nal, Bip, Pcp, Tic, Trp, Bth, Thi 또는 Dip인 화합물.
- 제10항에 있어서, Y는 A33-A34-A35-A36으로서, 여기서, A33은 Arg, Lys, homo-Arg, diethyl-homo-Arg, Lyw-ε-NH-R(여기서, R은 H, 가지난 또는 곧은 쇄 C1-C10알킬기, 또는 C6-C18아릴기이다), Cys 또는 Orn이고; A34는 Cys, Gln, Asn, Ala, Gly, N-Me-Gln, Aib 또는 Anb이며; A35는 Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-ε-NH-R(여기서, R은 H, 가지난 또는 곧은 쇄 C1-C10알킬기, 또는 C6-C18아릴기이다), C36또는 Orn이고; 및 A36은 방향족 아미노산, Cys 또는 그의 약제학상 허용되는 염인 화합물.
- 제12항에 있어서, 상기 화합물이 다음과 같은 식을 갖는 화합물: N-α-Ac-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2(서열확인번호 26) 또는 그의 약제학상 허용되는 염.
- 약제학상 허용되는 담체물질과 치료유효량의 제1항 및 제10항의 화합물을 포함하는 과잉의 장수 및 전해질의 분비를 감소시킬 수 있는 치료조성물.
- 포유동물에 치료유효량의 제14항의 조성물을 투여하는 것을 포함하는 포유동물에 있어서 과잉의 장수 및 전해질의 분비를 감소시키는 방법.
- 포유동물에 치료유효량의 제14항의 조성물을 투여하는 것을 포함하는 포유동물에 있어서 세포증식을 조절하는 방법.
- 포유동물에 치료유효량의 제14항의 조성물을 투여하는 것을 포함하는 포유동물에 있어서 영양분 수송을 증가시키는 방법.
- 포유동물에 치료유효량의 제14항의 조성물을 투여하는 것을 포함하는 포유동물에 있어서 지방분해를 조절하는 방법.
- 포유동물에 치료유효량의 제14항의 조성물을 투여하는 것을 포함하는 포유동물에 있어서 혈류를 조절하는 방법.
- 두 개의 제10항의 펩타이드, 또는 하나의 제1항의 펩타이드 및 하나의 제10항의 펩타이드중의 하나를 포함하는 이합체 화합물로서, 여기서 상기 이합체가 상기 두 펩타이드를 사이의 아미드 결합 또는 이황화물다리중 하나에 의해서 형성되는 이합체 화합물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3853493A | 1993-03-29 | 1993-03-29 | |
US10932693A | 1993-08-19 | 1993-08-19 | |
US08/038,534 | 1993-08-19 | ||
US08/109,326 | 1993-08-19 | ||
PCT/US1994/003380 WO1994022467A1 (en) | 1993-03-29 | 1994-03-29 | Analogs of peptide yy and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR960701653A true KR960701653A (ko) | 1996-03-28 |
Family
ID=26715298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950704035A KR960701653A (ko) | 1993-03-29 | 1994-03-29 | 펩타이드 yy의 유사체 및 그의 용도 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5604203A (ko) |
EP (1) | EP0692971A4 (ko) |
JP (1) | JPH08510205A (ko) |
KR (1) | KR960701653A (ko) |
CN (1) | CN1124927A (ko) |
AU (1) | AU685803B2 (ko) |
CA (1) | CA2157766A1 (ko) |
FI (1) | FI954559A (ko) |
HU (1) | HUT73494A (ko) |
NZ (1) | NZ265452A (ko) |
PL (1) | PL310897A1 (ko) |
SG (1) | SG52542A1 (ko) |
SK (1) | SK121895A3 (ko) |
WO (1) | WO1994022467A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180019616A (ko) * | 2015-06-12 | 2018-02-26 | 노보 노르디스크 에이/에스 | 선택적인 pyy 화합물 및 그것의 사용 |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516653A (en) * | 1993-12-28 | 1996-05-14 | Synaptic Pharmaceutical Corporation | DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof |
US5545549A (en) * | 1994-02-03 | 1996-08-13 | Synaptic Pharmaceutical Corporation | DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof |
US5989920A (en) | 1994-12-02 | 1999-11-23 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5 |
US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
US5912227A (en) * | 1995-01-27 | 1999-06-15 | North Carolina State University | Method of enhancing nutrient uptake |
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US6558708B1 (en) * | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
FR2735983B1 (fr) | 1995-06-29 | 1997-12-05 | Centre Nat Rech Scient | Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal |
AUPO029096A0 (en) * | 1996-06-05 | 1996-07-04 | Crc For Biopharmaceutical Research Pty Ltd | Npy y2 agonists |
AU772915B2 (en) * | 1996-06-05 | 2004-05-13 | Prince Of Wales Medical Research Institute Limited | Neuropeptide Y agonists |
US6696409B1 (en) | 1996-06-05 | 2004-02-24 | Prince Of Wales Medical Research Institute Limited (Powmr Ltd.) | Neuropeptide Y agonists |
US6713265B1 (en) | 1997-06-04 | 2004-03-30 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
US5916869A (en) * | 1997-06-13 | 1999-06-29 | North Carolina State University | Method of treating birds in ovo |
CA2321026A1 (en) * | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
US6046167A (en) * | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
US7745216B2 (en) * | 1999-02-10 | 2010-06-29 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
ATE482717T1 (de) | 1999-02-10 | 2010-10-15 | Curis Inc | Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
US6734166B1 (en) * | 2000-02-08 | 2004-05-11 | North Carolina State University | Method of reducing aluminum levels in the central nervous system |
AU2007200008B2 (en) * | 2000-04-10 | 2008-09-11 | Cedars-Sinai Medical Center | Methods for Manipulating Upper Gastrointestinal Transit, Blood Flow, and Satiety, and for Treating Visceral Hyperalgesia |
CA2431800C (en) | 2000-12-14 | 2014-07-08 | Amylin Pharmaceuticals, Inc. | Peptide yy and peptide yy agonists for treatment of metabolic disorders |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
DE60230818D1 (de) | 2001-09-24 | 2009-02-26 | Imp Innovations Ltd | Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
EP1474163A2 (en) | 2002-01-10 | 2004-11-10 | Imperial College Innovations Limited | Modification of feeding behavior |
US20060122106A1 (en) * | 2002-06-14 | 2006-06-08 | Amylin Pharmaceuticals, Inc | Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof |
US7186692B2 (en) * | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
EP1581245A2 (en) * | 2002-12-17 | 2005-10-05 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity |
US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
US7229966B2 (en) * | 2002-12-17 | 2007-06-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
EP1583549A4 (en) | 2003-01-17 | 2006-10-04 | Sod Conseils Rech Applic | YY PEPTIDE ANALOGS |
US7780973B2 (en) * | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
WO2005077094A2 (en) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
EP2417980A1 (en) * | 2004-02-11 | 2012-02-15 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
US20090186811A1 (en) * | 2004-03-17 | 2009-07-23 | Thue Schwartz | Y2 Selective Receptor Agonists for Therapeutic Interventions |
WO2005089790A2 (en) * | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y2/y4 selective receptor agonists for therapeutic interventions |
JP2007531713A (ja) * | 2004-03-17 | 2007-11-08 | 7ティーエム ファーマ エイ/エス | 治療的介入のためのy2選択性レセプターアゴニスト |
NZ555533A (en) | 2004-12-13 | 2010-03-26 | Amylin Pharmaceuticals Inc | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
US7410949B2 (en) * | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
US8283312B2 (en) * | 2005-02-04 | 2012-10-09 | The Research Foundation Of State University Of New York | Compositions and methods for modulating body weight and treating obesity-related disorders |
PA8660701A1 (es) * | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
US20090286723A1 (en) * | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
GB0504857D0 (en) * | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
BRPI0614649A2 (pt) * | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
BRPI0520566A2 (pt) * | 2005-09-21 | 2009-05-19 | 7Tm Pharma As | agonistas de receptores y2 seletivos para intervenções terapêuticas |
US8022035B2 (en) * | 2005-09-21 | 2011-09-20 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
US20070232537A1 (en) * | 2005-12-19 | 2007-10-04 | Nastech Pharmaceutical Company Inc. | Intranasal pyy formulations with improved transmucosal pharmacokinetics |
US20070197445A1 (en) | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
US20090099074A1 (en) * | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
GB0708226D0 (en) * | 2007-04-27 | 2007-06-06 | 7Tm Pharma As | Y-receptor agonists |
US8829159B2 (en) * | 2008-04-14 | 2014-09-09 | The General Hospital Corporation | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
US8299023B2 (en) | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
CN102348715B (zh) | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
JP5767582B2 (ja) | 2009-07-02 | 2015-08-19 | 武田薬品工業株式会社 | ペプチド及びその用途 |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
CN117462693A (zh) | 2012-02-27 | 2024-01-30 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
TWI661835B (zh) | 2013-11-15 | 2019-06-11 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性pyy化合物及其用途 |
JP6629198B2 (ja) | 2013-11-15 | 2020-01-15 | ノヴォ ノルディスク アー/エス | 35位にβ−ホモアルギニン置換を有するHPYY(1−36) |
BR112019004180A2 (pt) | 2016-08-28 | 2019-05-28 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization A R O | método de controle de infecções fúngicas em plantas. |
EP3746111B1 (en) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
US20230287040A1 (en) | 2019-11-13 | 2023-09-14 | Amunix Pharmaceuticals, Inc. | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS646294A (en) * | 1987-02-09 | 1989-01-10 | Ajinomoto Kk | Novel peptide derivative |
US5026685A (en) * | 1988-07-15 | 1991-06-25 | The Salk Institute For Biological Studies | NPY peptide analogs |
-
1994
- 1994-03-29 NZ NZ265452A patent/NZ265452A/en unknown
- 1994-03-29 SK SK1218-95A patent/SK121895A3/sk unknown
- 1994-03-29 CN CN94192277A patent/CN1124927A/zh active Pending
- 1994-03-29 SG SG1996005776A patent/SG52542A1/en unknown
- 1994-03-29 CA CA002157766A patent/CA2157766A1/en not_active Abandoned
- 1994-03-29 HU HU9502833A patent/HUT73494A/hu unknown
- 1994-03-29 WO PCT/US1994/003380 patent/WO1994022467A1/en not_active Application Discontinuation
- 1994-03-29 AU AU66214/94A patent/AU685803B2/en not_active Ceased
- 1994-03-29 KR KR1019950704035A patent/KR960701653A/ko not_active Application Discontinuation
- 1994-03-29 EP EP94913965A patent/EP0692971A4/en not_active Withdrawn
- 1994-03-29 PL PL94310897A patent/PL310897A1/xx unknown
- 1994-03-29 JP JP6522278A patent/JPH08510205A/ja active Pending
- 1994-10-24 US US08/329,151 patent/US5604203A/en not_active Expired - Lifetime
-
1995
- 1995-09-26 FI FI954559A patent/FI954559A/fi unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180019616A (ko) * | 2015-06-12 | 2018-02-26 | 노보 노르디스크 에이/에스 | 선택적인 pyy 화합물 및 그것의 사용 |
Also Published As
Publication number | Publication date |
---|---|
FI954559A0 (fi) | 1995-09-26 |
AU685803B2 (en) | 1998-01-29 |
CA2157766A1 (en) | 1994-10-13 |
HU9502833D0 (en) | 1995-11-28 |
SG52542A1 (en) | 1998-09-28 |
WO1994022467A1 (en) | 1994-10-13 |
SK121895A3 (en) | 1996-10-02 |
EP0692971A4 (en) | 1997-11-12 |
AU6621494A (en) | 1994-10-24 |
FI954559A (fi) | 1995-09-26 |
CN1124927A (zh) | 1996-06-19 |
NZ265452A (en) | 1997-09-22 |
EP0692971A1 (en) | 1996-01-24 |
US5604203A (en) | 1997-02-18 |
HUT73494A (en) | 1996-08-28 |
PL310897A1 (en) | 1996-01-08 |
JPH08510205A (ja) | 1996-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960701653A (ko) | 펩타이드 yy의 유사체 및 그의 용도 | |
JP2902115B2 (ja) | 新規アミリン作動薬ペプチドおよびその使用 | |
KR850000414B1 (ko) | 아실펩타이드의 제조방법 | |
IE57774B1 (en) | Grf analogs | |
AU589674B2 (en) | GRF analogs | |
ATE24919T1 (de) | Menschliches pankreatisches grf. | |
HUP0003592A2 (hu) | LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények | |
KR930007972A (ko) | 환상 혈관활성 펩티드 | |
KR880006263A (ko) | 신규의 캘시토닌 유도체의 제조방법 | |
ES2054365T3 (es) | Inhibicion de la via de la regla del n final en celulas vivas. | |
KR910002900A (ko) | 합성 펩티드 및 이를 함유하는 제약학적 조성물 | |
KR860009041A (ko) | GnRH길항제 IX의 제조방법 | |
KR980002066A (ko) | 변이형 인간 성장호르몬 및 그의 용도 | |
KR880011198A (ko) | 사이클릭 펩타이드 및 이의 제조방법 | |
Luis et al. | Characterization of VIP-and helodermin-preferring receptors on human small cell lung carcinoma cell lines | |
KR880013977A (ko) | 항응고제인 사이클릭 펩타이드 | |
KR927002373A (ko) | 성장 호르몬 분비 활성을 갖는 폴리펩타이드 화합물 | |
ATE546461T1 (de) | Gnrh analog von nicht-säugertieren und verwendung zur regulierung der fruchtbarkeit und der schwangerschaft | |
KR100360975B1 (ko) | 위장운동자극활성을가지는폴리펩티드 | |
GB1459303A (en) | Peptides and process for their manufacture | |
KR910009730A (ko) | 펩티드 | |
DE3687405D1 (de) | Aminosaeurederivate. | |
KR890006669A (ko) | 아미노산 유도체 | |
KR960004366A (ko) | 합성 펩타이드 유도체 및 이의염 | |
KR950702574A (ko) | 펩티드 폐 계면활성제 및 치료용 혼합물(Peptide Lung Surfactants and Therapeutic Combinations) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |